ATE470454T1 - Multimere konstrukte - Google Patents
Multimere konstrukteInfo
- Publication number
- ATE470454T1 ATE470454T1 AT05810409T AT05810409T ATE470454T1 AT E470454 T1 ATE470454 T1 AT E470454T1 AT 05810409 T AT05810409 T AT 05810409T AT 05810409 T AT05810409 T AT 05810409T AT E470454 T1 ATE470454 T1 AT E470454T1
- Authority
- AT
- Austria
- Prior art keywords
- fusion proteins
- domain
- flt
- multimerization
- neovascularization
- Prior art date
Links
- 108020001507 fusion proteins Proteins 0.000 abstract 3
- 102000037865 fusion proteins Human genes 0.000 abstract 3
- 101100381481 Caenorhabditis elegans baz-2 gene Proteins 0.000 abstract 2
- 206010029113 Neovascularisation Diseases 0.000 abstract 2
- 101100372762 Rattus norvegicus Flt1 gene Proteins 0.000 abstract 2
- 125000005647 linker group Chemical group 0.000 abstract 2
- 102000019034 Chemokines Human genes 0.000 abstract 1
- 108010012236 Chemokines Proteins 0.000 abstract 1
- 102000004127 Cytokines Human genes 0.000 abstract 1
- 108090000695 Cytokines Proteins 0.000 abstract 1
- 206010012689 Diabetic retinopathy Diseases 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 201000004681 Psoriasis Diseases 0.000 abstract 1
- 206010046851 Uveitis Diseases 0.000 abstract 1
- 206010064930 age-related macular degeneration Diseases 0.000 abstract 1
- 208000006673 asthma Diseases 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 239000003102 growth factor Substances 0.000 abstract 1
- 208000002780 macular degeneration Diseases 0.000 abstract 1
- 201000008482 osteoarthritis Diseases 0.000 abstract 1
- 230000001575 pathological effect Effects 0.000 abstract 1
- 229920001184 polypeptide Polymers 0.000 abstract 1
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 1
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 1
- 201000007914 proliferative diabetic retinopathy Diseases 0.000 abstract 1
- 108020003175 receptors Proteins 0.000 abstract 1
- 206010039073 rheumatoid arthritis Diseases 0.000 abstract 1
- 239000013598 vector Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
- C12P21/00—Preparation of peptides or proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/32—Fusion polypeptide fusions with soluble part of a cell surface receptor, "decoy receptors"
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
- C07K2319/735—Fusion polypeptide containing domain for protein-protein interaction containing a domain for self-assembly, e.g. a viral coat protein (includes phage display)
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Toxicology (AREA)
- Immunology (AREA)
- Wood Science & Technology (AREA)
- Physical Education & Sports Medicine (AREA)
- Rheumatology (AREA)
- Diabetes (AREA)
- Biotechnology (AREA)
- Cell Biology (AREA)
- General Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Pulmonology (AREA)
- Vascular Medicine (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Urology & Nephrology (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US60888704P | 2004-09-13 | 2004-09-13 | |
| US65820905P | 2005-03-04 | 2005-03-04 | |
| PCT/US2005/032320 WO2006031689A2 (en) | 2004-09-13 | 2005-09-13 | Multimeric constructs |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE470454T1 true ATE470454T1 (de) | 2010-06-15 |
Family
ID=36060586
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT05810409T ATE470454T1 (de) | 2004-09-13 | 2005-09-13 | Multimere konstrukte |
Country Status (16)
| Country | Link |
|---|---|
| US (4) | US7928072B2 (de) |
| EP (2) | EP1804835B9 (de) |
| JP (1) | JP4944032B2 (de) |
| CN (1) | CN101094688B (de) |
| AT (1) | ATE470454T1 (de) |
| BR (1) | BRPI0515264B1 (de) |
| CY (1) | CY1114155T1 (de) |
| DE (1) | DE602005021811D1 (de) |
| DK (2) | DK2229956T3 (de) |
| ES (2) | ES2407859T3 (de) |
| HK (1) | HK1144663A1 (de) |
| IL (2) | IL181839A0 (de) |
| MX (1) | MX2007002942A (de) |
| PL (2) | PL1804835T3 (de) |
| PT (2) | PT2229956E (de) |
| WO (1) | WO2006031689A2 (de) |
Families Citing this family (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PT2229956E (pt) * | 2004-09-13 | 2013-07-31 | Genzyme Corp | Contruções multiméricas |
| EP2666783B1 (de) * | 2007-09-25 | 2019-06-26 | Genzyme Corporation | Zusammensetzungen zur Hemmung der Interleukin-23 Wege |
| BRPI0908496A2 (pt) * | 2008-02-20 | 2019-01-15 | Genzyme Corp | inibição de angiogênese |
| WO2010019263A2 (en) * | 2008-08-15 | 2010-02-18 | Genzyme Corporation | Soluble flt constructs for treating cancers |
| US8697654B2 (en) * | 2008-12-18 | 2014-04-15 | E I Du Pont De Nemours And Company | Peptide linkers for effective multivalent peptide binding |
| LT2601214T (lt) | 2010-08-06 | 2018-02-26 | Genzyme Corporation | Vegf antagonistų kompozicijos ir jų panaudojimas |
| EP2655413B1 (de) | 2010-12-23 | 2019-01-16 | F.Hoffmann-La Roche Ag | Polypeptid-polynukleotid-komplex und verwendung bei der gezielten effektorrest-bereitstellung |
| DK2726101T3 (en) | 2011-06-30 | 2018-12-03 | Genzyme Corp | T-CELL ACTIVATION INHIBITORS |
| DK2744508T3 (en) * | 2011-08-19 | 2018-02-19 | Harvard College | VEGF BINING PROTEIN TO BLOCK ANGIOGENESES |
| CN102399292A (zh) * | 2011-09-14 | 2012-04-04 | 盛剑鹏 | 重组干细胞因子与免疫球融合蛋白及其制备 |
| US20130090375A1 (en) * | 2011-10-06 | 2013-04-11 | Cornell University | Virus-mediated delivery of bevacizumab for therapeutic applications |
| WO2013110120A1 (en) | 2012-01-24 | 2013-08-01 | Inter-K Pty Limited | Peptide agents for cancer therapy |
| EP2844267A4 (de) * | 2012-04-25 | 2016-02-24 | Ligacept Llc | Erbb-liganden-bindungsmoleküle mit breitem spektrum und verfahren zu deren verwendung |
| MX2014014804A (es) * | 2012-06-27 | 2015-02-12 | Hoffmann La Roche | Metodo para la elaboracion de conjugados de la region fc de anticuerpos que comprenden por lo menos una entidad de union que se une especificamente a un objetivo y usos del mismo. |
| WO2014001324A1 (en) | 2012-06-27 | 2014-01-03 | Hoffmann-La Roche Ag | Method for selection and production of tailor-made highly selective and multi-specific targeting entities containing at least two different binding entities and uses thereof |
| RS63820B1 (sr) | 2013-03-13 | 2023-01-31 | Genzyme Corp | Fuzioni prотеini kојi sadrže pdgf i vеgf vеzuјuće dеlоve i метоdе njihоvе upотrеbе |
| KR102049990B1 (ko) | 2013-03-28 | 2019-12-03 | 삼성전자주식회사 | c-Met 항체 및 VEGF 결합 단편이 연결된 융합 단백질 |
| WO2015120309A1 (en) * | 2014-02-06 | 2015-08-13 | Genzyme Corporation | Compositions and methods for treating and preventing macular degeneration |
| US9840553B2 (en) | 2014-06-28 | 2017-12-12 | Kodiak Sciences Inc. | Dual PDGF/VEGF antagonists |
| GB201412748D0 (en) * | 2014-07-17 | 2014-09-03 | Levicept Ltd | Therapeutic use of P75NTR neurotrophin binding protein |
| CN107207603A (zh) * | 2015-02-03 | 2017-09-26 | 吉安特科技股份有限公司 | 趋化因子‑免疫球蛋白融合多肽，其组合物、制备方法以及用途 |
| CN108712911A (zh) | 2015-12-30 | 2018-10-26 | 科达制药股份有限公司 | 抗体及其缀合物 |
| KR102205830B1 (ko) * | 2017-10-26 | 2021-01-21 | 주식회사 큐로진생명과학 | 솔루블 VEGFR-1 변이체 cDNA를 함유하는 rAAV를 포함하는 황반변성 치료용 조성물 |
| MX2020009152A (es) | 2018-03-02 | 2020-11-09 | Kodiak Sciences Inc | Anticuerpos de il-6 y constructos de fusion y conjugados de los mismos. |
| CN111655734A (zh) * | 2019-04-28 | 2020-09-11 | 广州市雷德生物科技有限公司 | 一种促进蛋白二聚体形成的拉链扣结构及其应用 |
| CN114786731A (zh) | 2019-10-10 | 2022-07-22 | 科达制药股份有限公司 | 治疗眼部病症的方法 |
| CN116769048A (zh) * | 2021-12-31 | 2023-09-19 | 康码（上海）生物科技有限公司 | 聚合分子、包括其的单一结构和多聚结构 |
Family Cites Families (69)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5049386A (en) | 1985-01-07 | 1991-09-17 | Syntex (U.S.A.) Inc. | N-ω,(ω-1)-dialkyloxy)- and N-(ω,(ω-1)-dialkenyloxy)Alk-1-YL-N,N,N-tetrasubstituted ammonium lipids and uses therefor |
| US5336603A (en) | 1987-10-02 | 1994-08-09 | Genentech, Inc. | CD4 adheson variants |
| US5567584A (en) | 1988-01-22 | 1996-10-22 | Zymogenetics, Inc. | Methods of using biologically active dimerized polypeptide fusions to detect PDGF |
| DE68926888T2 (de) | 1988-01-22 | 1997-01-09 | Zymogenetics Inc | Verfahren zur Herstellung von sekretierten Rezeptoranalogen |
| US5116964A (en) | 1989-02-23 | 1992-05-26 | Genentech, Inc. | Hybrid immunoglobulins |
| US5703055A (en) | 1989-03-21 | 1997-12-30 | Wisconsin Alumni Research Foundation | Generation of antibodies through lipid mediated DNA delivery |
| JPH03233530A (ja) | 1990-02-09 | 1991-10-17 | Fuji Photo Optical Co Ltd | カメラ |
| US5670488A (en) | 1992-12-03 | 1997-09-23 | Genzyme Corporation | Adenovirus vector for gene therapy |
| US5279833A (en) | 1990-04-04 | 1994-01-18 | Yale University | Liposomal transfection of nucleic acids into animal cells |
| US20020032313A1 (en) | 1991-03-29 | 2002-03-14 | Genentech, Inc. | Vascular endothelial cell growth factor antagonists |
| KR100335584B1 (ko) | 1992-10-28 | 2002-11-29 | 제넨테크, 인코포레이티드 | 혈관내피세포성장인자에대한길항제 |
| FR2702152B1 (fr) | 1993-03-03 | 1995-05-24 | Inst Nat Sante Rech Med | Virus recombinants et leur utilisation en thérapie génique. |
| EP0694042B1 (de) | 1993-03-25 | 2004-11-03 | Merck & Co. Inc. | Inhibitor des wachstumsfaktors für gefäss-endothelzellen |
| ATE301201T1 (de) | 1993-06-07 | 2005-08-15 | Vical Inc | Für die gentherapie verwendbare plasmide |
| US5919676A (en) | 1993-06-24 | 1999-07-06 | Advec, Inc. | Adenoviral vector system comprising Cre-loxP recombination |
| US6686200B1 (en) | 1993-08-31 | 2004-02-03 | Uab Research Foundation | Methods and compositions for the large scale production of recombinant adeno-associated virus |
| WO1995029993A1 (en) | 1994-04-28 | 1995-11-09 | The University Of Michigan | Gene delivery vector using plasmid dna packaged into an adenovirus and a packaging cell line |
| US5827702A (en) | 1994-10-31 | 1998-10-27 | Genentech, Inc. | Ocular gene therapy |
| US5910487A (en) | 1994-12-09 | 1999-06-08 | Genzyme Corporation | Cationic amphiphiles and plasmids for intracellular delivery of therapeutic molecules |
| US5650096A (en) | 1994-12-09 | 1997-07-22 | Genzyme Corporation | Cationic amphiphiles for intracellular delivery of therapeutic molecules |
| US5939401A (en) | 1994-12-09 | 1999-08-17 | Genzyme Corporation | Cationic amphiphile compositions for intracellular delivery of therapeutic molecules |
| US5719131A (en) | 1994-12-09 | 1998-02-17 | Genzyme Corporation | Cationic amphiphiles containing dialkylamine lipophilic groups for intracellular delivery of therapeutic molecules |
| US5948767A (en) | 1994-12-09 | 1999-09-07 | Genzyme Corporation | Cationic amphiphile/DNA complexes |
| US5747471A (en) | 1994-12-09 | 1998-05-05 | Genzyme Corporation | Cationic amphiphiles containing steroid lipophilic groups for intracellular delivery of therapeutic molecules |
| US5767099A (en) | 1994-12-09 | 1998-06-16 | Genzyme Corporation | Cationic amphiphiles containing amino acid or dervatized amino acid groups for intracellular delivery of therapeutic molecules |
| US5840710A (en) | 1994-12-09 | 1998-11-24 | Genzyme Corporation | Cationic amphiphiles containing ester or ether-linked lipophilic groups for intracellular delivery of therapeutic molecules |
| EP0821739B1 (de) | 1995-04-17 | 2003-06-18 | The Board Of Regents, The University Of Texas System | Adenovirus helfervirus system |
| SI1445322T2 (sl) | 1995-06-15 | 2012-10-30 | Crucell Holland Bv | Pakirni sistemi za humani rekombinantni adenovirus za gensko terapijo |
| US6013516A (en) | 1995-10-06 | 2000-01-11 | The Salk Institute For Biological Studies | Vector and method of use for nucleic acid delivery to non-dividing cells |
| JPH09154588A (ja) | 1995-10-07 | 1997-06-17 | Toagosei Co Ltd | Ｖｅｇｆ結合性ポリペプチド |
| CA2239366A1 (en) | 1996-01-05 | 1997-07-17 | Genetic Therapy, Inc. | Recombinase-mediated generation of adenoviral vectors |
| US5994317A (en) | 1996-04-09 | 1999-11-30 | Vical Incorporated | Quaternary cytofectins |
| US6100071A (en) * | 1996-05-07 | 2000-08-08 | Genentech, Inc. | Receptors as novel inhibitors of vascular endothelial growth factor activity and processes for their production |
| US5935936A (en) | 1996-06-03 | 1999-08-10 | Genzyme Corporation | Compositions comprising cationic amphiphiles and co-lipids for intracellular delivery of therapeutic molecules |
| ES2274549T3 (es) | 1996-09-24 | 2007-05-16 | MERCK & CO., INC. | Compuestos para la inhibicion de la angiogenesis por terapia de genes . |
| US5861397A (en) | 1996-10-03 | 1999-01-19 | Vical Incorporated | Piperazine based cytofectins |
| JP3837748B2 (ja) | 1997-01-17 | 2006-10-25 | 東亞合成株式会社 | Ｖｅｇｆ結合性ポリペプチド |
| US5925628A (en) | 1997-03-31 | 1999-07-20 | Genzyme Corporation | Cationic amphiphiles for intracellular delivery of therapeutic molecules |
| US5912239A (en) | 1997-04-04 | 1999-06-15 | Genzyme Corporation | Imidazole-containing cationic amphiphiles for intracellular delivery of therapeutic molecules |
| US5948925A (en) | 1997-05-06 | 1999-09-07 | Genzyme Corporation | Cationic amphiphiles containing linkers derived from neutral or positively charged amino acids |
| US5942634A (en) | 1997-05-09 | 1999-08-24 | Genzyme Corporation | Cationic amphiphiles for cell transfections |
| EP1173191A4 (de) | 1997-05-13 | 2004-12-01 | Univ California | Neuartige antiangiogenese peptidagenzien sowie ihre therapeutische und diagnostische verwendung |
| US5952916A (en) | 1998-05-28 | 1999-09-14 | Atras Auto Co., Ltd | Hammer-equipped emergency signal device |
| DE69832798T2 (de) | 1997-06-03 | 2006-09-14 | MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. | Regulatorische sequenzen für die in-vivo-expression einer heterologen dns-sequenz in endothelzellen und ihre verwendungen. |
| DE69838334T2 (de) | 1997-06-18 | 2008-06-12 | Merck & Co., Inc. (A New Jersey Corp.) | Kdr, ein menschlicher tyrosin kinase rezeptor |
| US5963622A (en) | 1997-07-29 | 1999-10-05 | 3Com Corporation | Mode signalling method and apparatus |
| AU9319198A (en) | 1997-09-19 | 1999-04-05 | Trustees Of The University Of Pennsylvania, The | Methods and vector constructs useful for production of recombinant aav |
| US5994136A (en) | 1997-12-12 | 1999-11-30 | Cell Genesys, Inc. | Method and means for producing high titer, safe, recombinant lentivirus vectors |
| WO1999057296A1 (en) | 1998-05-01 | 1999-11-11 | Genzyme Corporation | Partially deleted adenoviral vectors |
| US6378526B1 (en) | 1998-08-03 | 2002-04-30 | Insite Vision, Incorporated | Methods of ophthalmic administration |
| US7083950B2 (en) * | 1998-09-25 | 2006-08-01 | Regeneron Pharmaceuticals, Inc. | High affinity fusion proteins and therapeutic and diagnostic methods for use |
| US6472179B2 (en) * | 1998-09-25 | 2002-10-29 | Regeneron Pharmaceuticals, Inc. | Receptor based antagonists and methods of making and using |
| US6943153B1 (en) | 1999-03-15 | 2005-09-13 | The Regents Of The University Of California | Use of recombinant gene delivery vectors for treating or preventing diseases of the eye |
| CA2367375A1 (en) | 1999-03-15 | 2000-09-21 | Chiron Corporation | Use of recombinant gene delivery vectors for treating or preventing diseases of the eye |
| US7070959B1 (en) | 1999-06-08 | 2006-07-04 | Regeneron Pharmaceuticals, Inc. | Modified chimeric polypeptides with improved pharmacokinetic properties |
| NZ515913A (en) * | 1999-06-08 | 2004-01-30 | Regeneron Pharma | Modified chimeric polypeptides with improved pharmacokinetic properties |
| US7087411B2 (en) | 1999-06-08 | 2006-08-08 | Regeneron Pharmaceuticals, Inc. | Fusion protein capable of binding VEGF |
| US6821775B1 (en) | 2000-02-11 | 2004-11-23 | Genvec, Inc. | Viral vector encoding pigment epithelium-derived factor |
| AU2001292881A1 (en) | 2000-09-20 | 2002-04-02 | The Regents Of The University Of California | Use of recombinant gene delivery vectors for treating or preventing diseases of the eye |
| BR0116575A (pt) | 2001-01-09 | 2004-01-06 | Merck Patent Gmbh | Terapia combinada que usa inibidores de tirosina cinase receptora e inibidores de angiogênese |
| CA2434996A1 (en) * | 2001-01-25 | 2002-08-01 | Hill-Rom Services, Inc. | Hydraulic actuator apparatus for a surgical table |
| DE10109855A1 (de) * | 2001-03-01 | 2002-09-12 | Stanislawski Thomas | Polypeptide eines p53-Protein-spezifischen murinen alpha/beta T-Zell Rezeptors, diese kodierende Nukleinsäuren und deren Verwendung |
| US7078411B2 (en) * | 2001-05-16 | 2006-07-18 | Umdnj (Univ Of Medicine & Dentist. Of Nj) | Phospholipid transfer protein (PLTP) and cholestoral metabolism |
| NZ535100A (en) | 2002-03-20 | 2008-04-30 | Univ Florida | RAAV vector compositions and methods for the treatment of choroidal neovascularization |
| CU23178A1 (es) | 2002-04-15 | 2006-09-22 | Ct Ingenieria Genetica Biotech | INMUNOTERAPIA ACTIVA ANTIANGIOGéNICA |
| AU2004224122A1 (en) | 2003-03-26 | 2004-10-07 | Apogenix Gmbh | Improved Fc fusion proteins |
| PT2229956E (pt) * | 2004-09-13 | 2013-07-31 | Genzyme Corp | Contruções multiméricas |
| AR052056A1 (es) | 2004-12-17 | 2007-02-28 | Genentech Inc | Tratamiento antiangiogenico de enfermedades autoinmunitarias en pacientes que no han respondido a untratamiento previo |
| WO2010019263A2 (en) | 2008-08-15 | 2010-02-18 | Genzyme Corporation | Soluble flt constructs for treating cancers |
-
2005
- 2005-09-13 PT PT101651594T patent/PT2229956E/pt unknown
- 2005-09-13 PT PT05810409T patent/PT1804835E/pt unknown
- 2005-09-13 PL PL05810409T patent/PL1804835T3/pl unknown
- 2005-09-13 WO PCT/US2005/032320 patent/WO2006031689A2/en active Application Filing
- 2005-09-13 EP EP05810409A patent/EP1804835B9/de active Active
- 2005-09-13 DE DE602005021811T patent/DE602005021811D1/de active Active
- 2005-09-13 ES ES10165159T patent/ES2407859T3/es active Active
- 2005-09-13 EP EP10165159.4A patent/EP2229956B1/de active Active
- 2005-09-13 ES ES05810409T patent/ES2347340T3/es active Active
- 2005-09-13 DK DK10165159.4T patent/DK2229956T3/da active
- 2005-09-13 BR BRPI0515264A patent/BRPI0515264B1/pt not_active IP Right Cessation
- 2005-09-13 AT AT05810409T patent/ATE470454T1/de active
- 2005-09-13 CN CN2005800386237A patent/CN101094688B/zh active Active
- 2005-09-13 JP JP2007531408A patent/JP4944032B2/ja active Active
- 2005-09-13 DK DK05810409.2T patent/DK1804835T3/da active
- 2005-09-13 MX MX2007002942A patent/MX2007002942A/es active IP Right Grant
- 2005-09-13 PL PL10165159T patent/PL2229956T3/pl unknown
-
2007
- 2007-03-11 IL IL181839A patent/IL181839A0/en not_active IP Right Cessation
- 2007-03-12 US US11/716,794 patent/US7928072B2/en active Active
-
2010
- 2010-12-01 HK HK10111185.0A patent/HK1144663A1/xx not_active IP Right Cessation
-
2011
- 2011-02-02 US US13/019,432 patent/US8658602B2/en active Active
- 2011-11-01 IL IL216095A patent/IL216095A/en not_active IP Right Cessation
-
2013
- 2013-07-17 CY CY20131100605T patent/CY1114155T1/el unknown
-
2014
- 2014-01-31 US US14/170,257 patent/US9815892B2/en active Active
-
2017
- 2017-10-17 US US15/785,775 patent/US20180155417A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ATE470454T1 (de) | Multimere konstrukte | |
| EA202092093A1 (ru) | Композиции и способы перепрограммирования tcr с применением слитых белков | |
| EA201270802A1 (ru) | Димерные слитые белки vstm3 и связанные с ними композиции и способы | |
| DK2016102T3 (da) | Kimære T-cellereceptorer og tilhørende materialer og fremgangsmåder til anvendelse | |
| PA8738401A1 (es) | Proteinas de fusion de exendina | |
| DE602004028337D1 (de) | Fusionskonstrukte und deren verwendung zur produktion von antikörpern mit erhöhter fc rezeptor bindungsaffinität und effektorfunktion | |
| EA201390923A1 (ru) | Модифицированное антитело с улучшенным полупериодом существования | |
| WO2010003766A3 (en) | Multimeric tnf receptors | |
| CY1119774T1 (el) | Χρηση πρωτεϊνων εξωκυτταρικου πεδιου του fgfr1 για την αγωγη καρκινων χαρακτηριζομενων απο εξαρτωμενες απο προσδεμα ενεργοποιητικες μεταλλαξεις στο fgfr2 | |
| ATE505481T1 (de) | Fusionsproteine der tnf-superfamilie | |
| RU2015142999A (ru) | Слитые белки, содержащие связывающие части pdgf и vegf, и способы их применения | |
| MX2023001793A (es) | Ratones que producen proteinas de union que comprenden dominios vl. | |
| WO2008093688A1 (ja) | キメラFcγレセプター及び該レセプターを用いたＡＤＣＣ活性測定方法 | |
| ATE511544T1 (de) | Selektion von wirtszellen mit proteinexpression auf hohem niveau | |
| BR0313331A (pt) | antagonistas de receptor de nogo | |
| WO2010019263A3 (en) | Soluble flt constructs for treating cancers | |
| ATE555383T1 (de) | Lösliche heterodimere rezeptoren und ihre verwendung | |
| DK1532261T3 (da) | Fremgangsmåder og DNA-konstrukter til produktion af polypeptider med højt udbytte | |
| Lethbridge et al. | Immunological identification of the mouse H 4 histamine receptor on spinal cord motor neurons using a novel anti-mouse H 4 R antibody | |
| WO2007051063A3 (en) | Gpcr expressing cell lines and antibodies | |
| WO2010018444A3 (en) | An expression vector and a method thereof | |
| TW200510456A (en) | Materials and methods relating to g-protein coupled receptor oligomers | |
| WO2024073513A3 (en) | Chimeric receptors comprising interleukin 7 receptor (il7r) domains | |
| AR068038A1 (es) | Polipeptidos de la hormona de crecimiento modificada | |
| Tanase et al. | NEW TOOLS FOR DISCOVERING INHIBITORS OF THE RECEPTOR FOR ADVANCED GLYCATION END PRODUCTS |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| UEP | Publication of translation of european patent specification |
Ref document number: 1804835 Country of ref document: EP |